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QuiescenceS100B protein activates IKKβ/NF-κB within myoblasts, thereby inhibiting the expression of MyoD and the
MyoD-downstream effectors, myogenin and p21WAF1, and myoblast differentiation. Herein we show that
myoblasts downregulate S100B expression once transferred from proliferation medium to differentiation
medium via a p38 MAPK-driven transcriptional mechanism as well as a post-translational, proteasome-
dependent mechanism, and that myoblasts that have not been committed to differentiation resume
expressing S100B once transferred back to proliferation medium. Likewise, myoblasts downregulate S100B
expression once transferred to quiescence medium, and interference with S100B downregulation as obtained
by stable overexpression of the protein results in reduced acquisition of quiescence and a faster proliferation
upon transfer of the cells from quiescence medium to proliferation medium, compared to controls. These
latter effects are dependent on S100B-induced activation of JNK. Moreover, S100B reducesmyoblast apoptosis
in an MEK-ERK1/2, Akt, JNK, and NF-κB-dependent manner. However, myogenin+ myoblasts (i.e., myocytes)
and myotubes abundantly express S100B likely induced by myogenin. Our results suggest that (1) a timely
repression of S100B expression is required for efﬁcient myogenic differentiation; (2) S100B plays an
important role in the expansion of the activated (i.e., proliferating) myoblast population; (3) under conditions
associated with enhanced expression of S100B, the transition from proliferation to quiescence and from
quiescence to proliferation might be altered; and (4) S100B exerts different regulatory effects in myoblasts
and myocytes/myotubes/myoﬁbers. This article is part of a Special Issue entitled: 11th European Symposium
on Calcium.pean Symposium on Calcium.
: +39 075 585 7451.
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
S100B is a Ca2+-modulated protein of the EF-hand type that acts
both as an intracellular regulator and an extracellular signal [1].
Intracellular S100B has been involved in the regulation of cell cycle
progression and modulation of cell differentiation. Indeed, elevated
levels of S100B are detected in several malignant tumors [2,3]; S100B
negatively regulates the expression and function of the tumor
suppressor p53 [4]; forced expression of S100B in the PC12 neuronal
cell line results in enhanced proliferation and reduced responsiveness
to the differentiating effect of nerve growth factor [5]; expression of
S100B modulates chondrocyte terminal differentiation [6]; and
repression of S100B expression in astrocyte cell lines and primary
astrocytes results in reduced proliferation and migration and enhanced
differentiation [7].
Myogenesis is a multistep process by which mesenchymal cells
that are committed to myoblasts migrate to body sites of skeletal
muscle formation, proliferate, and eventually fuse with each other toform myotubes, the ultimate precursors of skeletal muscle ﬁbers [8–
10]. Similarly, in the adult skeletal muscle tissue that has undergone
damage mononucleated, quiescent satellite cells that coexist with
myoﬁbers and represent the adult stem cell pool of muscle tissue
become activated, emigrate, proliferate, and eventually fuse with each
other to form newmyoﬁbers and/or fuse with the damagedmyoﬁbers
to repair them [8–10]. The regulation of myoblast and satellite cell
proliferation and differentiation relies on the activity of extracellular
factors such as insulin and insulin-like growth factors, basic ﬁbroblast
growth factor, hepatocyte growth factor, leukemia inhibitory factor,
myostatin, transforming growth factor-β, members of theWnt family,
and several cytokines. These differentially govern myoblast and
satellite cell migration, proliferation, and/or differentiation by
affecting the activity of several intracellular pathways as well as the
activity of both muscle-speciﬁc (i.e., Myf5, MyoD, myogenin, and
MRF4) and non-speciﬁc transcription factors [8–10]. Among these,
myogenin plays a crucial role, as its expression is indispensable for
myogenic differentiation and marks the transition from myoblasts to
myocytes, i.e., cells that have irreversibly exited the cell cycle and are
fusion-competent [8–10]. Among the muscle non-speciﬁc transcrip-
tion factors NF-κB appears to play a fundamental role both in
physiological and pathological conditions [11–20].
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differentiation medium (DM) results in inhibition of differentiation,
stimulation of proliferation, and protection against apoptosis via
inactivation of the promyogenic p38 MAPK and activation of the
mitogenic ERK1/2 [21,22]. However, S100B is expressed in myoblast
cell lines [23] and in muscle satellite cells in situ [24], raising the
possibility that intracellular S100B might have a role in myoblast
proliferation/survival and/or differentiation. Indeed, increasing intra-
cellular S100B levels resulted in a dramatically reduced myogenic
differentiation via IKKβ/NF-κB-dependent inhibition of the expres-
sion of the myogenic transcription factor, MyoD, and its downstream
effectors, myogenin and p21WAF1, while inhibition of S100B expres-
sion resulted in a signiﬁcant acceleration of differentiation as a result
of reduction of NF-κB activity and consequent upregulation of MyoD
[24].
During muscle regeneration/repair, a fraction of activated satellite
cells neither participate in the formation of myotubes nor die by
apoptosis; this fraction of cells stop proliferating and reacquire a
quiescent status, thus reconstituting the pool of satellite cells [8–10].
The ability of S100B to modulate MyoD expression raised the
possibility that the protein might have a role in the transition of
myoblasts from proliferation to quiescence and/or the transition from
quiescence to proliferation, given that downregulation of MyoD
expression was shown to be required for proliferating myoblasts to
become quiescent [25], and activation of quiescentmyoblasts/satellite
cells was shown to result in expression of MyoD [26–28]. We show
here that (1) myoblasts in DM downregulate S100B mRNA and
protein as a consequence of both reduction of serum mitogens and
activation of the promyogenic p38 MAPK; (2) myoblast cultures
resume expressing S100B mRNA expression between 24 and 48 h in
DM; however, S100B protein levels remain low in non-fused
myogenin− myoblasts due to proteasomal degradation while myo-
genin+ myoblasts (i.e., myocytes) show highly abundant S100B; (3)
increasing S100B levels in myoblasts results in a reduced acquisition
of quiescence and an accelerated resumption of proliferation upon
switching the cells from quiescencemedium (QM) to growthmedium
(GM); and (4) enhancing S100B levels results in resistance to
apoptotic stimuli. These ﬁndings suggest that downregulation of
S100B is permissive for myogenic differentiation, and intracellular
S100B might promote the expansion of myoblasts following their
activation. The present results also suggest that conditions associated
with elevated S100B levels in proliferating myoblasts might interfere
with the homeostasis of the muscle satellite cell reserve pool.
2. Materials and methods
2.1. Cell culture
Wild-type (WT) L6 myoblasts, S100B-overexpressing L6 myo-
blasts (clone L6C8), andmock-transfected L6myoblasts (clone L6C11)
myoblasts were cultured for 24 h in DMEM supplemented with 10%
fetal bovine serum (FBS) (growth medium—GM) (Invitrogen), 100 U/
ml penicillin, and 100 μg/ml streptomycin, in a H2O-saturated 5% CO2
atmosphere at 37 °C before decreasing FBS to 2% (differentiation
medium—DM) to induce myoblast differentiation and myotube
formation. For analyses of effects of S100B on the transition of
myoblasts from proliferation to quiescence and from quiescence to
proliferation, L6C11 and L6C8 myoblasts were cultivated in GM for
24–48 h, then transferred to methionine-depleted DMEM, 1% FBS
(quiescence medium—QM) [26], and ﬁnally switched to GM. At each
time point, the cultures were analyzed for proliferation rate by
bromodeoxyuridine (BrdU) incorporation assay (see below). In some
experiments, myoblasts were cultivated in the presence of the NF-κB
inhibitor, pyrrolidine carbodithioic acid (PDTC) (Sigma) (10 μM), the
PI3K inhibitor, LY294002 (Calbiochem) (10 μM), the p38 MAPK
inhibitor, SB203580 (Calbiochem) (10 μM), the MEK-ERK1/2 inhibi-tor, PD98059 (Calbiochem) (30 μM), or the JNK inhibitor, SP600125
(Alexis, Lausen, Switzerland) (10 μM).
2.2. Transfections
S100B-overexpressing L6 myoblasts (clone L6C8) and mock-
transfected L6 myoblasts (clone L6C11) were obtained as described
[24], and S100B protein expression levels in L6C8 myoblasts were ~3
times higher than in L6C11myoblasts [24]. L6C8 and L6C11myoblasts
were used in experiments as described above and below, in media
containing G418 (200 μg/ml). WT L6 myoblasts were transiently
transfected withmyogenin expression vector or empty vector for 48 h
in GM. The cells were cultivated for 24 h in DM and analyzed for
S100B mRNA levels by real-time PCR or subjected to double
immunoﬂuorescence using a polyclonal anti-S100B antibody and a
monoclonal anti-myogenin antibody (see below).
2.3. Western blotting
Myoblastswere solubilizedwith 2.5% SDS, 10 mMTris–HCl, pH 7.4,
0.1 M dithiothreitol, 0.1 mM 0.1 mM tosylsulfonyl phenylalanyl
chloromethyl ketone protease inhibitor (Roche). Cell lysates were
subjected to Western blotting using the following antibodies:
polyclonal anti-phosphorylated (Thr180/Tyr182) p38 MAPK
(1:1000), a polyclonal anti-phosphorylated (Ser473) Akt (1:1000),
polyclonal anti-p38 MAPK (1:2000) and a polyclonal anti-Akt
(1:2000), polyclonal anti-phosphorylated (Thr202/Tyr204) ERK1/2
(1:2000) (all from Cell Signaling Technology), polyclonal anti-ERK1/2
(Sigma) (1:20,000), polyclonal anti-S100B (Epitomics) (1:1000),
polyclonal anti-phosphorylated NF-κB (p65) (Cell Signaling Technol-
ogy) (1:1000), polyclonal anti-NF-κB (p65) (Santa Cruz Biotechnol-
ogy) (1:500), polyclonal anti-phosphorylated (Thr183/Tyr185) SAPK/
JNK (1:1000; Cell Signaling Technology), and monoclonal anti-α-
tubulin (Sigma) (1:10,000). The immune reaction was developed by
enhanced chemiluminescence (SuperSignal West Pico, Pierce). Filters
were subjected to densitometric analysis of the pertinent immune
bands and their relative standard references (i.e., unphosphorylated
kinases and NF-κB or tubulin) using SCION Image.
2.4. Immunoﬂuorescence
S100B immunoﬂuorescence analyses was performed as described
[24] using a polyclonal anti-S100B antibody (SWant) (1:100). NF-κB
(p65) and myogenin immunoﬂuorescence analyses were performed
as described for S100B using a polyclonal anti-NF-κB antibody (p65)
(Santa Cruz Biotechnology) (1:1000) and a monoclonal anti-myo-
genin (Santa Cruz Biotechnology) (1:20). BrdU incorporation assay
was performed by immunoﬂuorescence. BrdU was added to cultures
2 h before ﬁxation with cold methanol at −20 °C and processing by
immunoﬂuorescence using a monoclonal anti-BrdU antibody (1:50,
Santa Cruz Biotechnology). BrdU+ and total cells were counted. Nuclei
were counterstained with DAPI. After mounting, the cells were
viewed on a DM Rb epiﬂuorescence microscope (Leica, Wetzlar,
Germany) equipped with a digital camera. For comparative analyses,
pictures were taken at a constant exposure time and gain in the same
experimental setting, and ten random ﬁelds/coverslip were photo-
graphed each by two independent investigators.
2.5. Reverse transcriptase-PCR and real-time PCR
Total RNA was extracted using the TRIzol reagent (Gibco BRL)
according to the manufacturer's instructions. The following primers
were employed for reverse transcriptase (RT)-PCR: rat S100B, forward
5′GCCCTCATTGATGTCTTCCATC3′ and reverse 5′AAGAACTCATGA-
CAGGCTGTGG3′; MyoD, forward 5′TGCAAGCGCAAGACCACTAA3′
and reverse 5′ACTGTAGTAGGCGGCGTCGTA3′; and rat GAPDH,
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CACAGCCTTG3′. After a 10-min incubation at 94 °C, 30 cycles were
performed as follows: denaturation at 94 °C for 60 s, annealing at
56 °C for 30 s, and extension at 72 °C for 30 s. Ampliﬁcation products
were resolved on a 2% agarose gel (Bio-Rad) and visualized by
ethidium bromide staining.
To detect S100BmRNA by real-time PCR, cDNAwas incubatedwith
the following primers: forward, 5′CTCTCACTTCCTGGAGGAAATC3′
and reverse 5′AAGAACTCATGACAGGCTGTGG3′, in a reaction volume
of 20 μl containing Real Master Mix and SYBR solution (Eppendorf).
Reaction mixtures were incubated in a Mx3000P Real-Time PCR
System (Stratagene) and analyzed by Multiplex Quantitative PCR
System. Housekeeping β-actin mRNA was used as a control (primers:
forward, 5′TCATCACTATCGGCAATGAG3′ and reverse, 5′CTTTACG-
GATGTCAACGTCA3′). Results are expressed as the relative change of
the S100B mRNA/β-actin mRNA ratio under the various experimental
conditions compared to the S100B mRNA/β-actin mRNA ratio in the
GM condition±SEM.
2.6. Measurement of apoptosis
To measure apoptosis, L6C11 and L6C8 myoblasts were seeded
onto 35-mm plastic dishes (18×104 cells/dish) in 10% FBS for 24 h,
washed with DMEM, and cultivated in DM as indicated in Fig. 5. Cells
were washed in PBS, resuspended, centrifuged (400×g, 7 min), and
processed for cell cycle analysis by propidium iodide staining and ﬂow
cytometry. Brieﬂy, the cell pellet was resuspended in 0.5 ml of
hypotonic ﬂuorochrome solution (50 μg/ml propidium iodide in 0.1%
sodium citrate plus 0.1% Triton X-100) in 12×75-mm polypropylene
tubes (BD Biosciences). The tubes were kept at 4 °C for at least 30 min
before ﬂow cytometric analysis. The propidium iodide ﬂuorescence of
individual nuclei was measured using a FACScan ﬂow cytometer (BD
Biosciences) at 488 nm. The percentages of apoptotic cells were
calculated using Cell FIT cell cycle analysis version 2.0.2 software.
Where appropriate, the inductor of apoptosis H2O2 (500 μM) was
added for 12 h.
2.7. Statistical analysis
Each experiment was performed at least three times. Representative
experiments are depicted in the ﬁgures unless stated otherwise. The
results are expressed as mean of three independent experiments±SEM.
Statistical analysis was performed using unpaired Student's t-test when
comparing two groups. The data were subjected to analysis of variance
(ANOVA) when comparing more than 2 parameters with SNK post hoc
analysis using a statistical software package (GraphPad Prism version
4.00, GraphPad Software, San Diego, CA, http://www.graphpad.com).
Statistical signiﬁcance was assumed when pb0.05.
3. Results
3.1. S100B expression levels decrease in myoblasts in
differentiation medium
As mentioned in the Introduction, gain-of-function and loss-of-
function experiments showed that intracellular S100B reduced L6,Fig. 1. Downregulation of S100B in differentiating myoblasts. (A) WT L6myoblasts were cult
of the p38 MAPK inhibitor, SB203580. Total mRNA was extracted, and S100B mRNA was qua
and subjected to immunoﬂuorescence to detect S100B. Nuclei were counterstained with
myoblasts in DM and the intense S100B ﬂuorescence intensity in myotubes. (C, D) Conditio
inhibitor, SB203580 (C), or the proteasome inhibitor, MG132 (D), as detailed in Materials an
(red signal) andmyogenin (green signal). Nuclei were counterstained with DAPI. Notice the t
absence of myotube formation and persistence of S100B in SB203580-treated myoblasts, a
cultivated in DM for 3 days and either subjected to double immunoﬂuorescence to detect S
another 2 days before double immunoﬂuorescence to detect S100B (red signal) and myog
merged images. The arrow in the upper panel points to an S100B+ myocyte. Notice that a
*Signiﬁcantly different from control (ﬁrst column from right; pb0.01, N=3). Scale bars=2C2C12 and primary myoblast differentiation via NF-κB activation and
NF-κB-dependent inhibition of MyoD expression in a dose-depen-
dent manner [24]. Speciﬁcally, either stable or transient over-
expression of S100B in myoblasts resulted in the inhibition of
myoblast differentiation and myotube formation, while S100B
knockdown resulted in enhanced myogenic differentiation. Thus,
intracellular S100B might participate in the regulation of the
myogenic process. To analyze this possibility further, we sought to
determine the levels of S100B expression in differentiating WT
myoblasts. Analyses of S100B mRNA levels showed that switching
WT L6 myoblasts to DM caused a rapid (i.e., within 3 h) decrease in
S100B mRNA with resumption of S100B expression between 24 and
48 h, as investigated by real-time PCR (Fig. 1A, upper panel). By
immunoﬂuorescence, we documented that S100B protein levels
started decreasing at ~6 h in DM with the protein being virtually
absent by 48 h in non-fused myogenin− myoblasts while being
expressed in myotubes and myogenin+ myocytes (Fig. 1B, C). Thus,
the decrease in serum mitogens consequent to the switch of the
cultures from GM to DM and/or differentiation cues might reduce
S100B expression levels in myoblasts in DM. Indeed, inhibition of
differentiation obtained by treating myoblasts in DM with SB203580,
a speciﬁc inhibitor of the promyogenic p38 MAPK [29,30], resulted in
the blockade of myogenic differentiation, as evidenced by the
absence of myogenin expression and myotube formation, and
reduced S100B mRNA and protein downregulation (Fig. 1A, lower
panel). The decrease and subsequent restoration of S100B mRNA
expression levels in control myoblasts in DM depicted in Fig. 1A,
lower panel, were shifted by ~24 h compared to Fig. 1A, upper panel,
likely due to the SB203580 vehicle, DMSO, which might alter the
kinetics of myoblast differentiation [31,32]. These results suggested
that downregulation of S100B in myoblasts in DM might be
dependent on activation of p38 MAPK and thus be part of the gene
program governing myogenic differentiation. However, myogenin+
myoblasts, i.e., myoblasts that had irreversibly exited the cell cycle
and started differentiating (myocytes) [8–10], were S100B+ (Fig. 1C,
DM, 1 d; also see Fig. 1E, upper panel, arrow). These results
suggested that the rapid and sustained activation of p38 MAPK
occurring upon transfer of myoblast cultures from GM to DM [29,30]
caused downregulation of S100B expression; however, myocytes
resumed expressing S100B.
We also found that treatment of myoblasts with the proteasome
inhibitor, MG132, during the ﬁrst 4 h of the switch from GM to DM or
during the last 4 h of the ﬁrst 24 h in DM resulted in enhanced
expression levels of S100B protein compared to respective internal
controls (Fig. 1D). These results suggested that not only was
transcription of s100b downregulated at the beginning of myoblast
differentiation under the action of p38 MAPK, S100B protein was also
rapidly degraded during the ﬁrst 24 h of the differentiation process.
Together with the observation that elevated S100B expression levels
in myoblasts in DM as obtained by overexpression of the protein
resulted in inhibition of the myogenic process while knockdown of
S100B resulted in stimulation of myogenesis [24], the present data
suggested that the decrease in S100B levels in differentiating
myoblasts might be permissive for myoblast differentiation, i.e.,
myoblasts need to reduce their S100B abundance for efﬁcient
differentiation to occur. However, irreversibly differentiatedivated in GM or DM as indicated in the absence (upper panel) or presence (lower panel)
ntiﬁed by real-time PCR. (B) WT L6 myoblasts were cultivated in GM or DM as indicated
DAPI. Notice the extremely faint S100B immunoﬂuorescence intensity in non-fused
ns were as in B, except that myoblasts cultures were treated either with the p38 MAPK
d methods, and cultures were subjected to double immunoﬂuorescence to detect S100B
ime-dependent decrease in S100B ﬂuorescence intensity in non-fusedmyoblasts in DM,
nd presence of S100B in MG132-treated myoblasts in DM. (E) WT L6 myoblasts were
100B (red signal) and myogenin (green signal) (upper panel) or transferred to GM for
enin (green signal) (lower panel). Nuclei were counterstained with DAPI. Shown are
fraction of non-fused myoblasts re-express S100B after transfer to GM (lower panel).
0 μm (B–D).
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myogenin.
However, when myoblast cultures made of myotubes and non-
fused myoblasts as obtained after 3 days in DM (a condition in which
mononucleated myogenin− myoblasts expressed low S100B and the
protein was expressed in myotube and myocytes—see Fig. 1E, upper
panel) were shifted back to GM for 2 days, a large fraction of non-
fused myogenin− myoblasts re-expressed S100B (Fig. 1E, lower
panel), thus supporting the notion that proliferation cues stimulate
S100B expression in myoblasts. The presence of S100B in myotubes
(Fig. 1B, C lower panel on left, and D) was likely to result from
expression of the protein after myocyte fusion, although we could not
exclude that a fraction of myotube S100B derived from the actual
fusion of S100B+ myocytes. Similar results were obtained using
C2C12 mouse myoblasts (data not shown).
Also, we noted that downregulation of S100B preceded the
expression of myogenin as at 6 h in DM myoblasts showed reduced
expression of S100B, compared to the GM condition, in the absence of
myogenin protein expression (Fig. 1C), and that at 1 day in DM
myoblasts showing a faint myogenin immunoﬂuorescence still wereFig. 2. Transient transfection of myoblasts with myogenin results in upregulation of S100B. M
in GM and then transferred to DM. Myoblasts were analyzed for S100B mRNA expression lev
anti-myogenin antibody (B). *Signiﬁcantly different from internal control (pb0.01, N=3).S100B− (Fig. 1C). Thus, it is possible that p38 MAPK-induced
myogenin [8–10,29,30] stimulates S100B expression in myocytes. In
this context, it is relevant that myogenin recognition sites are found in
the s100b promoter. To have preliminary information about the role of
myogenin as an S100B inducer, we transiently transfected myoblasts
with myogenin expression vector and looked for S100B expression:
ectopic expression of myogenin in myoblasts resulted in a signiﬁcant
increase in S100B mRNA levels and S100B immunoﬂuorescence
intensity in myocytes at 24 h in DM (Fig. 2). Collectively, the present
results suggested that activation of p38 MAPK at early myoblast
differentiation stages caused induction of myogenin [33] and down-
regulation of S100B; however, p38 MAPK-induced myogenin caused
S100B expression at later differentiation stages.
3.2. S100B in myoblasts interferes with acquisition of quiescence and
accelerates resumption of proliferation after quiescence
As non-fused myoblasts at relatively late stages in DM are
candidate either to die by apoptosis or to acquire a quiescent status
[8–10], we analyzed the possibility that S100B might affect theyoblasts were transiently transfected with myogenin expression vector or empty vector
els by real-time PCR (A) and by double immunoﬂuorescence using an anti-S100B and an
Scale bar=50 μm (A).
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quiescence to proliferation. To this end, we cultivated L6C11 (mock-
transfected) and L6C8 (S100B-overexpressing) myoblasts in GM forFig. 3. Overexpression of S100B in L6 myoblasts interferes with acquisition of quiescenc
cultivated in GM, QM and again in GM as detailed in Materials and methods. At each time
proliferation rate (upper panel). Selected ﬁelds of the experiments above are shown in the b
Nuclei were counterstained with DAPI. Shown are merged images. (B) Conditions were as in
were analyzed for MyoD expression by RT-PCR. (C, D) Conditions were as in A, except thatW
(D). Notice the decrease in S100B expression in myoblasts in QM and the re-expression of S
control (pb0.05, N=3). Scale bar=50 μm (A).48 h and then in QM for increasing time intervals up to 48 h, a
condition in which myoblasts become progressively arrested in the
G0/G1 phase of the cell cycle [26], after which each clone was switchede. (A) L6C11 (mock-transfected) and L6C8 (S100B-overexpressing) myoblasts were
point, cultures were subjected to BrdU incorporation assay for measurements of the
ottom panel. BrdU+ myoblasts were identiﬁed by immunoﬂuorescence (green signal).
A, except that after the quiescence period, myoblasts were transferred to DM and cells
T myoblasts were analyzed for S100B expression by RT-PCR (C) or immunoﬂuorescence
100B upon transfer of myoblasts from QM to GM. *Signiﬁcantly different from internal
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~28%, respectively) were proliferating as investigated by a BrdU
incorporation assay after 2 days in GM (Fig. 3A), pointing to lack of
obvious effects of overexpression of S100B on the proliferation of
asynchronously proliferating L6 myoblasts in GM. However, whereas
the percentage of BrdU+ L6C11 (control) myoblasts dropped to
14.33%, 4.53%, and 1.47% at 6, 24, and 48 h by the switch from GM to
QM, respectively, the percentage of BrdU+ L6C8 (S100B-overexpres-
sing) myoblasts amounted to 13.75%, 6.39%, and 6.27% at the same
time points (Fig. 3A). Also, switching myoblasts from QM to GM
caused no changes in the percentage of BrdU+ L6C11 myoblasts at 6 h
(i.e., 1.47% vs. 1.68%) and a rise to 7.33% and 27.05% at 24 and 48 h,
respectively, while the percentages of BrdU+ L6C8 myoblasts
increased to 7.41%, 20.18%, and 25.96% at these same time points
(Fig. 3A). Similar results were obtained by FACS analyses of cell cycle
(data not shown). Thus, increasing S100B levels in myoblasts resulted
in a reduced acquisition of quiescence and an accelerated resumption
of proliferation after quiescence. Moreover, the cell numbers at the
end of the experiment in Fig. 2A were ~5- and 3-fold higher in L6C8
and L6C11 myoblasts, respectively, compared with the cell numbers
measured at the end of the initial 48-h period in GM (data not shown).
Qualitatively similar results were obtained when L6C11 and L6C8
myoblasts were switched from QM to DM (data not shown). We
veriﬁed that, like proliferating L6C11 myoblasts, quiescent L6C11
myoblasts did not express MyoD and that MyoD was expressed in
L6C11 myoblasts upon their transfer from QM to DM, but not GM, as
investigated by RT-PCR (Fig. 3B), in accordance with the ﬁnding that
differentiating but not proliferating L6 myoblasts express MyoD [24].
By contrast, L6C8myoblasts did not expressMyoD at any time point in
this experimental setting (Fig. 3B) in keeping with S100B-dependent
repression of MyoD expression in myoblasts [24].
S100B (mRNA and protein) was signiﬁcantly downregulated in
WT L6 myoblasts during quiescence (Fig. 3D). This was not due to a
general reduction of transcription and/or protein synthesis in QM
because expression levels of several other proteins remained
unchanged in QM compared to GM (see below). These results
supported the conclusion that the decrease in serum mitogens
consequent to the transfer of myoblasts from GM to DM or QM
might contribute to S100B downregulation and that S100B down-
regulation is required both for efﬁcient differentiation and for
attainment of quiescence.3.3. Differential NF-κB (p65) activation in proliferating control and
S100B-overexpressing myoblasts
As mentioned in the Introduction, S100B activates the IKKβ/IκBα/
NF-κB (p65) module in myoblasts, thereby repressing MyoD
expression and inhibiting myogenic differentiation [24]. Thus, we
analyzed L6C11 and L6C8 myoblasts for NF-κB (p65) activation by
immunoﬂuorescence and Western blotting during proliferation,
quiescence, and again proliferation. Nuclear localization of NF-κB
(p65), an index of NF-κB activation, was detected during the
proliferation phase in a small (~13%) percentage of L6C11 myoblasts
and in a high (≥95%) percentage of L6C8 myoblasts (Fig. 3A) in
accordance with previous ﬁndings [24], while no nuclear transloca-
tion of NF-κB (p65) was observed in either L6C11 or L6C8 myoblasts
at 48 h in QM (Fig. 4A). By contrast, a high (≥95%) percentage of L6C8
myoblasts showed nuclear translocation of NF-κB (p65) at 6 h and
24 h after their transfer from QM to GM (Fig. 4A) while parallel L6C11
myoblasts exhibited 0 and ~6% nuclear translocation of NF-κB (p65)Fig. 4. S100B activates NF-κB (p65) in L6C8myoblasts in GM, but not late phases of quiescenc
GM after QM and subjected to immunoﬂuorescence to detect NF-κB (p65). Nuclei were co
blotting to detect phosphorylated (activated) NF-κB (p65). Notice that S100B does not activa
Scale bar=20 μm (A).at 6 h and 24 h, respectively (Fig. 4A). Levels of phosphorylated NF-κB
(p65) in the two myoblast clones (Fig. 4B) paralleled those of nuclear
NF-κB (p65) as shown in Fig. 4A. Thus, S100B might function as a
regulator of some step(s) along a signaling cascade impinging on the
IKKβ/IκBα/NF-κB (p65) module during myoblast proliferation, and
for S100B to activate NF-κB (p65) metabolic and/or signaling
pathways activated by extracellular cues might be required.3.4. Differential activation of ERK1/2, Akt, and JNK in proliferating and
quiescent control and S100B-overexpressing myoblasts
Next, we analyzed the phosphorylation (activation) levels of
ERK1/2, Akt, JNK, and p38MAPK, i.e., signaling kinases playing speciﬁc
roles in myoblast proliferation and differentiation [29,30,33–36], in
L6C11 and L6C8 myoblasts at deﬁnite steps during the transition from
proliferation to quiescence and from quiescence to proliferation. No
differences in the phosphorylation levels of the promyogenic p38
MAPK were observed between L6C11 and L6C8 myoblasts at the
single time points examined (data not shown). By contrast,
phosphorylation levels of ERK1/2 were higher in L6C8 than in L6C11
myoblasts at 24 h after plating in GM and at the beginning of the
quiescence period, becoming reduced at 24 h of quiescence at which
time point ERK1/2 phosphorylation levels were the same in the two
myoblast clones (Fig. 5A). However, by 6 h of switch of the cells from
QM to GM L6C8 (S100B-overexpressing) myoblasts exhibited signif-
icantly higher ERK1/2 phosphorylation levels compared to L6C11
myoblasts (Fig. 5A). Akt phosphorylation levels were similar in the
two myoblast clones in GM and at the beginning of the quiescence
period decreasing thereafter with a surprisingly larger decrease in
L6C8 than in L6C11 myoblasts (Fig. 5A). By contrast, by 6 h of the
switch of cells from QM to GM Akt phosphorylation levels were much
higher in L6C8 (S100B-overexpressing) than in L6C11 myoblasts
(Fig. 5A). JNK phosphorylation levels were the same in the two
myoblast clones in GM and higher in L6C8myoblasts in QM and by 6 h
of the switch of cells from QM to GM compared to L6C11 myoblasts
(Fig. 5A). However, inhibition of MEK-ERK1/2 did not alter the
proliferation rate of either myoblast clone during the ﬁrst 24 h in QM
or the ﬁrst 24 h after the transfer of the cells from QM to GM,
compared to the respective control, and it resulted in death-induced
detachment of 100% of L6C11 and L6C8 at 48 h in QM (Fig. 5B). Also,
inhibition of PI3K-Akt caused a ~40% reduction of proliferation rate at
6 h in QM in bothmyoblast clones, no changes in the proliferation rate
of either clone at 24 h in QM or at 6 h and 24 h by the transfer of
cultures from QM to GM compared to the respective control, and
death-induced detachment of 100% of L6C11 and L6C8 at 48 h in QM
(Fig. 5B). Moreover, the higher levels of ERK1/2 and NF-κB (p65)
activation detected in L6C8 myoblasts at 24 h in GM compared to
L6C11 myoblasts also did not correlate with the myoblast prolifera-
tion rate as this was the same in the twomyoblast clones (Figs. 4B and
5A). Lastly, activation levels of NF-κB (p65) were relatively low and
the same in individual clones beyond 1 h in QM (see Fig. 4). Thus,
S100B ability to stimulate ERK1/2 and NF-κB (p65) and, under deﬁnite
conditions, Akt, might support functions other than stimulation of
myoblast proliferation. Instead, inhibition of JNK resulted in reduction
of proliferation of L6C8myoblasts at 48 h in QM and at 6 and 24 h after
the transfer of cells from QM to GM (Fig. 5B). Thus, S100B appeared to
stimulate myoblast proliferation in QM and after the transfer of the
cells from QM to GM via activation of JNK.
Knockdown of S100B by a speciﬁc S100B siRNA in WT L6 or L6C11
myoblasts did not result in an accelerated acquisition of quiescencee. (A) L6C11 (control) and L6C8myoblasts were cultivated in either GM, QM, or again in
unterstained with DAPI. (B) Same as in A, except that cells were subjected to Western
te NF-κB (p65) in QM. *Signiﬁcantly different from respective controls (pb0.05, N=3).
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Fig. 5. Activation status of ERK1/2, Akt, and JNK in L6C11 and L6C8myoblasts in GM and QM. (A) Conditions were as in Fig. 4, except that cells were subjected toWestern blotting for
detection of phosphorylated ERK1/2, Akt, and JNK. (B) Conditions were as described in the legend to Fig. 2A, except that cultivation of L6C11 and L6C8 myoblasts was carried out in
the presence of either the PI3K-Akt inhibitor, LY294002, or the MEK-ERK1/2 inhibitor, PD98059, or the JNK inhibitor, SP600125. *Signiﬁcantly different from respective controls
(pb0.05, N=3).
1100 C. Tubaro et al. / Biochimica et Biophysica Acta 1813 (2011) 1092–1104and a decelerated resumption of proliferation after quiescence (data
not shown) likely because myoblasts physiologically downregulated
S100B in QM (Fig. 3C, D) and because the effect of serum mitogens
upon transfer of myoblasts from QM to GM likely overcame a
potential anti-proliferative effect of S100B knockdown. Collectively,
these results thus suggested that myoblasts need to downregulate
S100B to attain quiescence and that conditions associated with higher
than normal levels of S100B in myoblasts might affect the transition
from proliferation to quiescence and from quiescence to proliferation.
3.5. Intracellular S100B protects myoblasts against apoptotic stimuli
By FACS analysis, we measured ~90% and 70% less apoptotic cells
in L6C8 myoblasts compared to L6C11 myoblasts in GM and DM,
respectively, and a higher resistance of L6C8 myoblasts to H2O2-
induced apoptosis compared to L6C11 myoblasts (Fig. 6). Thus,
overexpression of S100B in L6 myoblasts resulted in an increased cell
survival. The anti-apoptotic effect of S100B was dependent on NF-κBactivity in part because treatment of cells with the NF-κB inhibitor,
PDTC, resulted in a reduced ability of L6C8 myoblasts to resist
apoptotic stimuli and PDTC treatment increased the percentage of
apoptotic L6C8 myoblasts (Fig. 6). However, inhibition of NF-κB in
S100B-overexpressing myoblasts did not result in apoptosis levels
similar to control myoblasts, suggesting that S100B might protect
myoblasts against apoptosis by additional mechanisms. We found
that inhibition of either MEK-ERK1/2, PI3K-Akt, or JNK resulted in
enhanced apoptosis in control and S100B-overexpressing myoblasts
in GM (Fig. 6B); however, JNK activity appeared to play a major in the
protective effect of S100B against apoptosis in S100B-overexpressing
myoblasts (Fig. 6B). In contrast, in L6C11 (control) myoblasts in DM
MEK-ERK1/2 and JNK, but not PI3K-Akt activity appeared to
counteract apoptotic stimuli (Fig. 6B), with a marginal if any role for
S100B because little if any S100Bwas expressed in the vast majority of
mononucleated myoblasts under these conditions (see Fig. 1C).
Instead, the anti-apoptotic effect exerted by overexpressed S100B in
DM appeared to be dependent mainly if not exclusively on MEK-
GM, 2 d
L6C11 L6C8
L6C11 L6C8 L6C11 L6C8
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Fig. 6. S100B protects myoblasts against spontaneous and H2O2-induced apoptosis via activation of NF-κB and ERK1/2, Akt and/or JNK depending on culture conditions. (A, B) L6C11
and L6C8 myoblasts were cultivated in GM for 2 days (A) or in DM for 2 days (B), treated with either 0.5 mM H2O2 (during the last 12 h of cultivation) or 10 μM PDTC (during the
cultivation time in GM or DM, respectively), and analyzed for apoptosis by FACS. *Signiﬁcantly different from control (ﬁrst column from left; pb0.05, N=3). **Signiﬁcantly different
from the corresponding L6C11 sample and internal control (pb0.05, N=3). (C, D) Conditions were as in A and B, respectively, except that myoblasts were cultivated in the absence
(DMSO) or presence of either the PI3K-Akt inhibitor, LY294002, or the MEK-ERK1/2 inhibitor, PD98059, or the JNK inhibitor, SP600125. *Signiﬁcantly different from internal control
(pb0.05, N=3).
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overexpressed S100B might exert its anti-apoptotic effect via
activation of MEK-ERK1/2 and PI3K-Akt, likely impinging on NF-κB,
and JNK in highly proliferating myoblasts, and via activation of MEK-
ERK1/2, likely impinging on NF-κB, in myoblasts in DM.
4. Discussion
We have shown that the expression level of the myogenesis
inhibitor S100B rapidly decreases upon transfer of myoblasts fromGM
to DM, and this appears to be permissive for myoblast differentiation
to occur. Indeed, elevated levels of S100B in myoblasts as obtained by
overexpression of the protein result in inhibition of myogenic
differentiation, and knockdown of S100B results in enhanced
differentiation [24]. Both the activation of the promyogenic p38
MAPK and the reduction of serum mitogens consequent to the
transfer of myoblasts from GM to DM are responsible for the rapid
decrease in S100B mRNA and protein levels suggesting that S100B
expression is transcriptionally regulated negatively by p38 MAPK and
positively by signaling pathways activated by serummitogens (Fig. 7).
Also, post-translational events concur to reduce S100B levels in
myoblasts in DM as treatment of myoblasts in DM with the
proteosomal inhibitor MG132 reduces the decrease in S100B protein
abundance and because S100B protein expression levels remain low
in non-fused myoblasts at relatively late differentiation stages, i.e.,
when S100B mRNA abundance has been restored. Future studies
should elucidate the mechanism whereby p38 MAPK activity down-
regulates S100B expression at early myoblast differentiation stages.
Our present results suggest that this does not occur via upregulationof myogenin. Indeed, myocytes (i.e., differentiated myoblasts) and
myotubes (which express high myogenin levels) show highly
abundant levels of S100B suggesting that cells of the myogenic
lineage re-express S100B at and/or near completion of the differen-
tiation program. In this context, the relatively high expression levels
of S100B mRNA measured at 48 h in DM might reﬂect S100B
production by myocytes and myotubes. This pattern of S100B
expression proﬁle, i.e., high levels in proliferating myoblasts followed
by low levels in differentiating myoblasts and high levels again in
myocytes/myotubes, is reminiscent of the time course of S100B
expression in differentiating astrocytes [7] and chondrocytes [6].
Thus, a decrease in S100B protein abundance appears to be permissive
for subsequent cell differentiation, with fully differentiated cells re-
expressing the protein. Notably, the s100b promoter contains
myogenin recognition sites, raising the possibility that re-expression
of S100B in myocytes is positively regulated by myogenin. Indeed,
ectopic expression of myogenin results in a signiﬁcant increase in
S100B mRNA levels and the intensity of S100B immunoﬂuorescence
in myocytes in DM. It is tempting to speculate that the relatively high
expression levels of S100B in proliferating cells serve the function of
avoiding precocious differentiation thereby favoring cell expansion
and/or survival and that conditions causing inability of cells to
downregulate S100B abundance might result in defective differenti-
ation and potentially contribute to their neoplastic transformation. In
this latter respect, it is interesting that S100B expression levels are
high in several tumor cell types [1–4]. However, mechanisms should
exist through which S100B expression levels are being restored in,
e.g., mature astrocytes and chondrocytes [1], myoﬁbers [37], and
quiescent muscle satellite cells [24] in normal physiological
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important role as a positive regulator of S100B expression in
myocytes/myotubes and that S100B might exert different regulatory
activities in proliferating myoblasts and myocytes/myotubes/myoﬁ-
bers. We cannot exclude that other S100 family members that are
expressed in myoblasts participate in or antagonize myogenic
differentiation. However, we note that changes in S100B abundance
are sufﬁcient to alter the myogenic process [24] and the proliferation/
quiescence/proliferation sequence (this work) (Fig. 7).
We also asked whether the decrease in S100B protein abundance
in myoblasts in DM might be functionally linked to the destiny of
those myoblasts that, after exiting the cell cycle, do not enter the
differentiation program and either die by apoptosis or become
quiescent [8–10]. Quiescent myoblasts, i.e., myoblasts that neither
proliferate nor differentiate, express Myf5, but not MyoD [26–28], and
repression of MyoD expression has been suggested to be required for
myoblasts to acquire a quiescent status [25]. We found that L6C8
(S100B-overexpressing, MyoD−) myoblasts were signiﬁcantly resis-
tant to quiescence cues and resumed proliferation faster than control
myoblasts when transferred from QM to GM. Thus, although the
ﬁnding that overexpression of S100B results in repression of MyoD
expression and inhibition of myoblast terminal differentiation [24] is
reminiscent of the situation found in the case of the differentiation-Fig. 7. Schematic representation of the proposed regulatory effects of intracellular S100B in
S100B stimulates NF-κB activity with resultant inhibition of MyoD and myogenin expressio
which the asterisk refers). Switching myoblasts to differentiation medium results in downre
reduction of serum mitogens. However, S100B becomes re-expressed in myocytes likely un
(e.g., after 3 days in differentiation medium), S100B is found in myocytes and myotubes. (B)
S100B expression levels decrease and proliferation is arrested, whereas S100B-overexpres
Transfer of control myoblasts from quiescence medium to proliferationmedium restores the
being kept signiﬁcantly high during the ﬁrst 24 h likely via activation of JNK. Moreover, ove
ERK1/2, and NF-κB.defective MyoD-/- satellite cells [25,38], important differences exist
between these two cases. For example, the proliferation rate of S100B-
overexpressing L6 myoblasts does not differ from that of control
myoblasts under standard proliferation conditions, i.e., using asyn-
chronously proliferating cells, as opposed to the reduced proliferation
rate of MyoD−/− satellite cells [25,38]. Moreover, as discussed above,
when switched to QM, S100B-overexpressing myoblasts are less
prone to enter quiescence and show a faster proliferation rate upon
return to GM compared to control myoblasts.
Although a positive correlation exists between activation of
MEK-ERK1/2, PI3K-Akt, and NF-κB (p65) and proliferation in
S100B-overexpressing myoblasts, these factors do not mediate
S100B-dependent proliferation in L6C8 myoblasts. Rather, the
enhanced activation of MEK-ERK1/2, PI3K-Akt, and NF-κB (p65)
in these cells appears to be protective against apoptosis, and S100B-
dependent proliferation of myoblasts is dependent on activation of
JNK, a kinase known to support myoblast proliferation [39]. JNK
activity also plays an important role in S100B-dependent protection
of proliferating myoblasts from apoptosis. The molecular mecha-
nism(s) whereby S100B regulates ERK1/2, Akt, JNK, and NF-κB
(p65) activities remain(s) to be elucidated. The scaffolding protein
IQGAP1, one intracellular S100B target protein [40], might link
S100B to JNK via Rac1 given IQGAP's ability to target Rac1 [41], theproliferating, differentiating, and quiescent myoblasts. (A) In proliferating myoblasts,
n once the myoblasts are being transferred to differentiation medium (see Ref. [24] to
gulation of S100B expression due both to activation of the promyogenic p38 MAPK and
der the action of p38 MAPK-induced myogenin. At relatively late differentiation stages
Upon transfer of control myoblasts from proliferation medium to quiescence medium,
sing myoblasts show a signiﬁcantly high proliferation rate likely via activation of JNK.
starting conditions, whereas the proliferation rate of S100B-overexpressing myoblasts is
rexpression of S100B results in protection against apoptosis via activation of JNK, Akt,
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ability of Rac1 to activate JNK [42–45]. Future studies will verify or
deny this possibility.
Collectively, our results suggest that when expressed in relatively
high amounts in myoblasts, S100B might support a certain amount of
proliferation in the absence of mitogenic cues (i.e., in QM) and amplify
effects of mitogenic cues after the switch of myoblasts from QM to GM.
These observationsmight explainwhy overexpression of S100B does not
result in an enhanced proliferation rate of myoblasts at late cultivation
time points in GM or in DM: effects of serummitogens are likely tomask
the mitogenic effect of intracellular S100B, which instead become
evident in QMand at the beginning of resumption of proliferation during
the transition from QM to GM. These effects are not the result of S100B-
dependent repression of MyoD expression because MyoD is not
expressed in proliferating or quiescent L6 myoblasts (24 and Fig. 2B).
Thus, besides modulating myoblast differentiation and myotube
formation via NF-κB (p65)-dependent repression of MyoD expression,
when present in sufﬁcient amounts intracellular S100B stimulates
myoblast proliferation in QM to some extent and accelerates prolifer-
ation of activatedmyoblasts. Based on this, we propose that intracellular
S100B might contribute to the expansion of activated myoblasts by
stimulating their proliferation while countering differentiation cues (i.e.,
precocious differentiation) as observed in the cases of neuronal cells [5],
chondrocytes [6], and astrocytes [7].
Moreover, upregulation of S100B expression translates into
reduced apoptosis via NF-κB activation, suggesting that S100B
might increase myoblast and, potentially, satellite cell survival by
counteracting death-inducing stimuli, which also might be beneﬁcial
during the muscle regeneration process. Recent evidence suggests
that MyoD has a role in myoblast apoptosis via downregulation of
anti-apoptotic genes and that the repression of MyoD expression that
occurs in quiescent myoblasts/satellite cells might be functional to
their survival [46]. In the present case, the anti-apoptotic activity of
S100B in proliferating myoblasts cannot be attributed to repression of
MyoD expression because proliferating L6 myoblasts do not express
MyoD [24]: S100B exerts anti-apoptotic effects in myoblasts via
activation of MEK-ERK1/2, PI3K/Akt, JNK, and NF-κB. However, we
cannot exclude that S100B's ability to inhibit MyoD expression in
differentiating L6C8 (S100B-overexpressing) myoblasts might con-
tribute to reduce their apoptosis in DM.
NF-κB activity was reported to be responsible for apoptosis in
myoblasts transplanted into diseasedmuscles [47], and inhibition of NF-
κB in mdx mice, a mouse model of Duchenne muscular dystrophy, was
shown to improve the ability of muscle progenitor cells to proliferate,
form myotubes, and repair damaged myoﬁbers [18,48]. The peculiar
genetic background and the occurrence of inﬂammation in the case of
mdxmice [18,48] and the stress caused by the transplantation in the case
of cell therapy of diseased muscles might be responsible for the
detrimental effect of activation of NF-κB. Also, inhibition of NF-κB
activity via systemic administration of NF-κB inhibitors to mdx mice
likely reduced or blocked NF-κB activity in inﬁltratingmacrophageswith
consequent reduction of the local inﬂammatory response and amelio-
ration of pathological signs [18]. However, activation of NF-κB in
myogenic cell lines was shown to result in an increased expression of
anti-oxidant enzymes and myoblast survival upon exposure to oxidant
stress [49]. Thus, the outcome and, likely, the intensity of NF-κB
activation may vary, resulting in beneﬁcial or detrimental effects
depending on the myoblasts' microenvironment and, as proposed
here, S100B expression levels.
Notably, basal levels of expression of S100B in wild-type myoblasts
do not affect the dynamics of transition from proliferation to quiescence
and from quiescence to proliferation, as S100B knockdown via RNA
interference, albeit causing a signiﬁcant reduction of NF-κB transcrip-
tional activity and enhanced myogenic differentiation [24], does not
result in changes in the proliferation/quiescence/proliferation sequence.
This is likely because myoblasts physiologically downregulate S100B inDM (i.e., in the presence of reduced mitogens) and QM (i.e., in the
presence of reduced mitogens and absence of methionine), which
incidentally indicates that S100B expression in myoblast cultures is
highly dependent on the presence of mitogens, absence of differentia-
tion cues, and protein synthesis. Thus, only at relatively high levels
S100B appears to affect the proliferation/quiescence/proliferation
sequence in vitro. It is thus possible that modulation of differentiation
and regulation of acquisition and maintenance of a quiescent status
might represent distinct outcomes of the S100B activity in myoblast
cultures, requiring different expression levels of the protein. However,
the in vitro conditions required for studying certain molecular aspects of
quiescent myoblasts (see above) are not comparable with the in vivo
conditions: for example, myoblasts made quiescent in vitro show
extremely reduced S100B (mRNA and protein) expression levels
(Fig. 2C, D) while quiescent satellite cells in muscle tissue do express
S100B [24]. Thus, at the physiological levels found in satellite cells in
muscle tissue, S100B might participate in the process of expansion of
activated satellite cells, e.g., in case of skeletal muscle injury. Future
studies using animal models of muscle damage should shed light on this
issue. Interestingly, elevation of S100B expression levels in astrocytes in
the aging brain is a well-established notion [1–3], and several functional
and pathophysiological correlations between increased expression of
S100B and Alzheimer's disease and other neuroinﬂammatory states
have been described [1–3,50–54]. Recent results indicate that satellite
cells isolated from Vastus Lateralis muscle of healthy aged humans
express remarkably higher levels of S100B compared to young humans
and that knockdown of S100B in aged satellite cells rescues their
differentiation potential in part [55], thus establishing a positive
correlation between high S100B expression levels in muscle satellite
cells and defective muscle tissue regenerative potential in aged people
(sarcopenia).
In conclusion, the present data suggest that reduction of S100B
protein abundance is required for myoblasts to differentiate and form
myotubes and that defective downregulation of S100B expression
levels results in defective myogenic differentiation as well as in an
altered acquisition of the quiescent state by those myoblasts that do
not enter the differentiation program. These effects might be
important in case of enhancement of S100B expression levels as
observed in aged human satellite cells [55] and presumed to occur in
Down syndrome [56,57] in consequence of S100B human gene
mapping to chromosome 21q22.3 [58]. On the other hand, S100B
might play an important role during the regeneration phase of
damaged skeletal muscles in physiological conditions, contributing to
support myoblast expansion.
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